Banner
HomeBest Practices → Gastric Cancer Risk Doubled With Long-term PPI Use

Gastric Cancer Risk Doubled With Long-term PPI Use Print E-mail
Written by Megan Brooks | Medscape   
Wednesday, 01 November 2017 00:00
 
Use of a proton-pump inhibitor (PPI) after Helicobacter pylori eradication more than doubles the risk for gastric cancer, according to a population-based study from Hong Kong. The "clear dose-response and time-response" trend in PPI use and gastric cancer risk observed suggests the need for "caution when prescribing long-term PPIs to these patients even after successful eradication of H. pylori," write Wai Keung Leung, MBChB, MD, from Queen Mary Hospital, Hong Kong, and colleagues. The study was published online October 31 in Gut.
 


Banner
Website design, development, and hosting provided by
Netphiles